Advicenne Announces Long-Term Results of the European Clinical Development Program for ADV7103

Regulatory News: Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering

Related Keywords

Milan ,Lombardia ,Italy ,Canada ,Vilnius ,Vilniaus Apskritis ,Lithuania ,Paris ,France General ,France ,French ,Marta Giaccari ,Advicenne Euronext ,Didier Laurens ,European Renal Association ,European Society Of Pediatric Nephrology ,Regulatory News ,Euronext Growth Paris ,Renal Tubular Acidosis ,Renal Association ,Focused Orals ,Pediatric Nephrology ,European Society ,Marketing Approval ,Euronext Paris ,Registration Document ,Advicenne ,Nnounces ,Song ,Term ,Results ,European ,Linical ,Development ,Program ,Dv7103 ,